Share This Author
Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance
- E. Glaze, Amy L. Lambert, J. Tomaszewski
- Biology, MedicineCancer Chemotherapy and Pharmacology
- 29 June 2005
With the recent approval of 17-DMAG for clinical use, the data generated from these preclinical studies will provide guidance to clinicians as they administer this drug to their patients.
Cyclic hyperalimentation: an optimal technique for preservation of visceral protein.
Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride).
AbstractThe effectiveness of Bentyl (dicyclomine hydrochloride) 40 mg 4 times daily was evaluated in an ambulatory population with recent irritable bowel syndrome (IBS). During the 2-week…
Steady‐State Pharmacokinetics of Zonisamide, an Antiepileptic Agent for Treatment of Refractory Complex Partial Seizures
- G. Kochak, J. Page, R. Buchanan, R. Peters, C. Padgett
- Medicine, BiologyJournal of clinical pharmacology
- 1 February 1998
A 56‐day pharmacokinetic study of zonisamide was conducted in 24 healthy volunteers, and steady state was achieved in 29 days including two dose escalations, and in an average of 15 days from the last dose adjustment, demonstrating that zonisamia is not an autoinducer.
Indole-3-carbinol, but not its major digestive product 3,3'-diindolylmethane, induces reversible hepatocyte hypertrophy and cytochromes P450.
Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro
The greater susceptibility of humans and dogs to the myelotoxicity of camptothecins, compared to mice, was evident in vitro at the cellular level, explaining why the curative doses of TPT and 9AC in mice with human tumor xenografts are not achievable in patients.
Effects of leuprolide in the treatment of central precocious puberty.
Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption.
Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man.
The results suggest that some inducing agents may be used to minimize individual variations in drug metabolism where such variations create therapeutic problems by exposing patients who slowly metabolize certain drugs to toxicity and other patients who rapidly metabolize some drugs to undertreatment.
Genetic Control of Drug Levels in Man: Antipyrine
Individuals with identical genotypes exhibited significantly less variability in antipyrine halflife than did genetically different individuals (dizygotic twins), therefore variations in antipyrsine metabolism appear to be determined genetically rather than environmentally.